Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registry
M Dubinsky, Meena Thayu(Children's Hospital of Philadelphia), S. Kugathasan, Kung‐Pei Tang, Jeffrey Hyams(Herlev Hospital), J.C. Escher, Nicholas Masel, Salvatore Cucchiara(Massachusetts General Hospital), Sibylle Koletzko(LMU Klinikum), Anne M. Griffiths(University of Toronto), Harland S. Winter(Massachusetts General Hospital), Richard B. Colletti(Greenville College), James Markowitz(Philadelphia University), R Baldassano(Herlev Hospital), B. D. Gold(Emory University), F. Ruemmele, Gigi Veerman(Statistics Belgium), J. M. Fell(Chelsea and Westminster Hospital NHS Foundation Trust), William A. Faubion(Mayo Clinic in Arizona)
Journal of Crohns & Colitis
January 1, 2016
Cited by 0
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k